hailshadow-istockphoto-com
Hailshadow / iStockphoto.com
26 July 2018Asia

AbbVie faces hepatitis C patent challenge in India

In India, a non-profit organisation and an advocacy group have united to take on a patent covering pibrentasvir, part of the drug combination that forms AbbVie’s hepatitis C product Mavyret.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
24 July 2018   The Patent Trial and Appeal Board has rejected another challenge to a Gilead-owned patent covering the company’s hepatitis C medicines.
Asia-Pacific
15 February 2017   India-based Initiative for Medicines, Access & Knowledge has filed four patent challenges against patents covering hepatitis C drugs in a bid to ensure access to affordable treatment.

More on this story

Americas
24 July 2018   The Patent Trial and Appeal Board has rejected another challenge to a Gilead-owned patent covering the company’s hepatitis C medicines.
Asia-Pacific
15 February 2017   India-based Initiative for Medicines, Access & Knowledge has filed four patent challenges against patents covering hepatitis C drugs in a bid to ensure access to affordable treatment.

More on this story

Americas
24 July 2018   The Patent Trial and Appeal Board has rejected another challenge to a Gilead-owned patent covering the company’s hepatitis C medicines.
Asia-Pacific
15 February 2017   India-based Initiative for Medicines, Access & Knowledge has filed four patent challenges against patents covering hepatitis C drugs in a bid to ensure access to affordable treatment.